Here is the expert synthesis:
---
The single most promising near-term path to field-deployable blight-resistant American chestnuts is The American Chestnut Foundation's (TACF) recurrent genomic selection (RGS) program, which builds on three decades of backcross breeding. Thirty years of backcross breeding to capture the natural blight resistance of Chinese chestnut, involving over 50,000 trees, has resulted in approximately 500 trees that contain on average only 12% Chinese chestnut DNA but have inherited at least some blight resistance; however, the overall number and degree of resistance is insufficient for use as a restoration population without further breeding efforts. TACF's current strategy layers genomic tools onto this foundation. Using DNA-based predictions, researchers have shown it is possible to identify blight-resistant trees that are still mostly American chestnut, preserving the height, growth, and forest competitiveness that made the species ecologically important. With genome-enabled breeding, the next generation of trees is expected to have twice the average blight resistance of the current population, with an average of 75 percent American chestnut ancestry. TACF is pursuing this through four parallel breeding tracks—maximizing blight resistance, balancing blight and Phytophthora root rot (PRR) resistance simultaneously, maximizing PRR resistance, and selecting among large surviving American chestnuts— all while maintaining a minimum of 70% American chestnut ancestry. This multi-track approach addresses the critical but often overlooked threat of Phytophthora root rot, which TACF considers essential to incorporate into all breeding efforts in order to produce material adapted across the species' historic range.
The most significant recent scientific development is USDA-APHIS's formal deregulation, in August 2026, of SUNY-ESF's genetically engineered Darling 54 American chestnut. After thorough review, APHIS determined that the modified American chestnut is unlikely to pose a greater plant pest risk than the unmodified comparator and is therefore no longer subject to regulation governing the introduction of organisms developed using genetic engineering. This is the first transgenic forest tree deregulated for conservation purposes in the United States. The tree carries a wheat-derived oxalate oxidase (OxO) gene that breaks down the oxalic acid the blight fungus uses to kill host tissue. This matters because it opens the door, at least in principle, to crossing transgenic blight tolerance into TACF's backcross lines. TACF's stated strategy includes testing the stacking of resistance through crosses between OxO lines and moderately blight-resistant backcross trees to combine the blight resistance of transgenic trees with the PRR resistance found in some of TACF's backcross breeding lines. However, the practical impact is still constrained, because while USDA review is now complete, Darling trees are still undergoing regulatory review by the U.S. EPA and FDA, and this is a continued part of a process by which the safety of transgenic plants must be verified before they are publicly distributed or widely planted.
The biggest remaining bottlenecks are both institutional and scientific. On the regulatory side, the outstanding EPA and FDA reviews of the Darling transgenic line create deep uncertainty about the timeline for any large-scale planting of OxO-containing trees. The USDA decision is important, but it does not settle whether large-scale restoration planting can begin. Furthermore, the earlier revelation that all completed field trials had inadvertently used the Darling 54 event rather than the petitioned Darling 58 event eroded institutional confidence; TACF discontinued support of development of the Darling 58 cultivar in December 2023, in part due to the mistaken use of Darling 54 in all completed field trials. Scientifically, there are fundamental scaling challenges. A 2025 field study in Forest Ecology and Management found that backcross seedlings exhibited similar growth and survival compared to non-transgenic American chestnut, and that selection of optimal American chestnut varieties for restoration may be context dependent —highlighting that performance varies by silvicultural setting and that no single genotype will suit all sites. Producing the genetically diverse, regionally adapted, multi-disease-resistant populations needed for forest-scale reintroduction across the Appalachian range remains an enormous logistical challenge that will take additional breeding generations even with genomic acceleration.
New funding would have the highest impact-per-dollar if directed toward three areas. First, expanding the genotyping and phenotyping infrastructure for TACF's RGS program is the rate-limiting step; the program relies on genotyping to select the top 10% of offspring that have predicted disease resistance greater than their parents while retaining high American chestnut ancestry , and throughput in sequencing and controlled inoculation trials directly determines the speed of each breeding cycle. Second, multi-site, long-term field trials that evaluate both blight and PRR performance under realistic forest conditions are essential but chronically underfunded—tree breeding requires decades of data, and without sustained field infrastructure the genomic predictions cannot be validated at scale. Third, should EPA and FDA clearance be obtained, investment in crossing transgenic Darling lines with the most resistant backcross hybrids could yield stacked resistance combining the OxO transgene with polygenic blight and PRR resistance, which Jared Westbrook, director of science at TACF, has supported in principle, while cautioning that a failed rollout could hurt public trust in future biotech trees. Given the long generation times of forest trees, every year of delayed investment compounds the timeline to restoration, making sustained, patient capital the single most valuable input the program currently lacks.